Vafseo and the Future of Renal Anemia Treatment – Akebia’s Vision for a $5B Kidney Disease Portfolio

Renal anemia is one of the most common complications of chronic kidney disease (CKD). As kidney function declines, the production of erythropoietin (EPO) decreases, resulting in reduced stimulation of red blood cell production in the bone marrow and the development of anemia.

For many years, the standard treatment of renal anemia has relied primarily on two approaches:

Erythropoiesis-stimulating agents (ESAs) such as epoetin alfa or darbepoetin

Iron supplementation

While these therapies have been effective, they also have clear structural limitations.

First, there is the burden of repeated injections. Many patients require long-term ESA therapy, and repeated injections can reduce treatment convenience and adherence.

Second, there is the risk of antibody formation. In rare cases, recombinant EPO treatment has been associated with pure red cell aplasia (PRCA) caused by anti-EPO antibodies.

Third, there are limitations in iron metabolism. ESA treatment alone does not always optimize iron utilization, often requiring additional iron supplementation.

This is why Vafseo (vadadustat) represents an important therapeutic evolution.

A New Approach: HIF-PH Inhibition

Vafseo belongs to the class of HIF-PH (Hypoxia-Inducible Factor Prolyl Hydroxylase) inhibitors.

Instead of directly replacing EPO through injections, Vafseo works by activating the body’s natural hypoxia response pathway. This leads to:

1. Stabilization of hypoxia-inducible factor (HIF)

2. Increased endogenous EPO production

3. Improved iron absorption and utilization

4. Enhanced red blood cell production

In other words, Vafseo helps the body stimulate erythropoiesis through a more physiologic pathway rather than relying solely on exogenous ESA injections.

This distinction matters. Compared with traditional injectable ESA therapy, Vafseo offers several potential advantages:

Oral administration rather than repeated injections

A more physiologic stimulation of erythropoiesis

Potential improvement in iron handling and utilization

A treatment profile that may fit more naturally into long-term renal anemia management

For these reasons, HIF-PH inhibitors such as Vafseo are increasingly viewed as a meaningful shift in the treatment paradigm for renal anemia.

Why Dialysis Network Adoption Matters

The commercial opportunity for Vafseo is not determined only by the drug itself. It is also determined by how the U.S. dialysis market functions.

Unlike many therapeutic categories, prescribing in dialysis is heavily influenced by large dialysis organizations and network-level treatment protocols, not simply by individual physicians acting independently.

In the United States, two companies dominate this ecosystem:

Fresenius Medical Care

DaVita

Together, Fresenius Medical Care and DaVita account for the majority of U.S. dialysis patients. Because of this market structure, adoption by Fresenius Medical Care or DaVita can have an outsized impact on the commercial trajectory of a renal drug.

That is why network adoption is so important. If Vafseo is incorporated into treatment protocols within Fresenius Medical Care or DaVita, the drug could rapidly gain access to a very large dialysis population. This is not simply a matter of incremental prescribing. It can become a scale event.

For Akebia, broad adoption within Fresenius Medical Care and DaVita would likely represent one of the clearest signals that Vafseo is moving toward standard-of-care relevance in dialysis-related renal anemia.

Akebia’s Long-Term Kidney Franchise Strategy

According to Akebia’s investor materials, the company is not positioning Vafseo as an isolated asset. Rather, it is presenting a broader strategy built around three kidney-focused therapies, with a long-term goal of reaching approximately $5 billion in annual revenue across the renal portfolio.

This matters because it shifts the discussion from a single-product biotech story to a potential renal therapeutics platform.

If Akebia is successful, Vafseo could serve as the leading commercial entry point, while additional renal pipeline assets expand the company’s presence across the kidney disease treatment landscape.

What a $5B Revenue Milestone Could Mean for Valuation

If Akebia were to achieve $5 billion in annual revenue, the valuation implications would be substantial.

Commercial-stage biotechnology companies often trade at a Price-to-Sales (PSR) multiple of approximately 4x to 6x, depending on growth, margins, and market leadership.

Using that framework:

$5B revenue × 4x PSR = $20B market capitalization

$5B revenue × 5x PSR = $25B market capitalization

$5B revenue × 6x PSR = $30B market capitalization

At that valuation range, Akebia would no longer be viewed as a small-cap biotechnology company. It would be reclassified by the market as a major renal therapeutics company.

Under a conservative interpretation of that scenario, the company could reasonably support a share price of at least $80, with upside beyond that depending on execution, market penetration, and durability of revenue growth.

Conclusion

Renal anemia treatment has long been dominated by injectable ESA therapy and iron supplementation. Vafseo introduces a different approach: an oral HIF-PH inhibitor that stimulates erythropoiesis through the body’s own physiologic response pathways.

That alone is clinically meaningful. But from a commercial perspective, the real inflection point may come from dialysis network adoption.

If Fresenius Medical Care and DaVita ultimately adopt Vafseo more broadly within their dialysis systems, the revenue acceleration could become much more visible. And if Akebia succeeds in building out the broader three-drug kidney portfolio described in its investor materials, the company could transform from a small biotechnology firm into a major leader in renal medicine.

In that scenario, a future valuation consistent with at least an $80 share price would no longer look speculative, but strategic.

---

Appendix: A Veterinarian’s Perspective on Future Animal Health Development

As a veterinarian who treats cardio-renal disease in companion animals, I find the mechanism of Vafseo especially compelling from a comparative medical perspective.

Chronic kidney disease is common in dogs and cats, and renal anemia is also a frequent clinical problem in veterinary medicine. In practice, veterinarians often prescribe:

Iron supplementation

EPO or darbepoetin injections

However, repeated injections can be burdensome for both patients and caregivers, and immune-related concerns remain relevant.

For that reason, the emergence of an oral drug class that stimulates erythropoiesis through the body’s oxygen-sensing pathway is highly interesting. Given that many foundational insights into hypoxia biology and physiologic adaptation were first clarified through animal research, it is reasonable to expect that this therapeutic mechanism could eventually attract attention in veterinary pharmaceutical development as well.

From the perspective of a veterinarian managing cardio-renal patients, I would welcome the future development of similar agents for animal health applications, particularly for chronic kidney disease-associated renal anemia in dogs and cats.